People with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence may benefit from treatment with Lynparza (olaparib).
People with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence may benefit from treatment with Lynparza (olaparib) for the year after completing chemotherapy, surgery or radiation according to the recently completed OlympiA study. While Herceptin (trastuzumab) can reduce recurrence in those with HER2-positive breast cancer, no targeted therapy was available to keep cancer from returning in people with HER2-negative, BRCA-positive breast cancer until the development of olaparib, a PARP inhibitor. The American Society of Clinical Oncology (ASCO) updated their guidelines to recommend olaparib in the year following breast cancer treatment in these patients. Read more in our XRAY review.
Patient Advocate Faces Thyroid Cancer Decades After Surviving Breast Cancer
September 5th 2023‘I feel like I've gone to continuing education classes as an advocate through reentering the health system in the cancer space,’ FORCE executive director and founder Sue Friedman, a breast cancer survivor who recently received a diagnosis of thyroid cancer, tells CURE.
Read More
Stepping Up Again for Hereditary Cancer Prevention
February 25th 2023On Feb. 6, HB 2783 was introduced into the Arizona House. Hopefully this bill will help address some of the issues surrounding genetic testing, genetic counseling, and insurance coverage for those who might be at risk for hereditary cancer. My wife died of a cancer that was totally preventable. Nobody should die of a preventable cancer.
Read More